{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:06:23Z","timestamp":1793196383096,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR067738"],"award-info":[{"award-number":["R01 AR067738"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30 DA033934"],"award-info":[{"award-number":["P30 DA033934"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA033930"],"award-info":[{"award-number":["R01 DA033930"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.neuropharm.2021.108820","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T15:18:05Z","timestamp":1633360685000},"page":"108820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Non-conserved residues dictate dopamine transporter selectivity for the potent synthetic cathinone and psychostimulant MDPV"],"prefix":"10.1016","volume":"200","author":[{"given":"Tyler W.E.","family":"Steele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Spires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9430-2856","authenticated-orcid":false,"given":"Charles B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Glennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Dukat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5288-1669","authenticated-orcid":false,"given":"Jose M.","family":"Eltit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108820_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","article-title":"Basic local alignment search tool","volume":"215","author":"Altschul","year":"1990","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib2","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1074\/jbc.M109.072587","article-title":"Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter","volume":"285","author":"Andersen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2021.108820_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/srep15650","article-title":"Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter","volume":"5","author":"Andersen","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2021.108820_bib4","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1021\/acschemneuro.8b00138","article-title":"Effects of N-Alkyl-4-Methylamphetamine optical isomers on plasma membrane monoamine transporters and abuse-related behavior","volume":"9","author":"Battisti","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108820_bib5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/npp.2012.204","article-title":"Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products","volume":"38","author":"Baumann","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108820_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00213-013-3223-5","article-title":"Abuse-related and abuse-limiting effects of methcathinone and the synthetic \"bath salts\" cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats","volume":"231","author":"Bonano","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108820_bib7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00213-013-2967-2","article-title":"Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of \"bath salts,\" produce opposite effects at the human dopamine transporter","volume":"227","author":"Cameron","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108820_bib8","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/bph.12061","article-title":"Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter","volume":"168","author":"Cameron","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ceca.2015.06.013","article-title":"Amphetamine activates calcium channels through dopamine transporter-mediated depolarization","volume":"58","author":"Cameron","year":"2015","journal-title":"Cell Calcium"},{"key":"10.1016\/j.neuropharm.2021.108820_bib10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41594-019-0253-7","article-title":"Monoamine transporters: structure, intrinsic dynamics and allosteric regulation","volume":"26","author":"Cheng","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nature17629","article-title":"X-ray structures and mechanism of the human serotonin transporter","volume":"532","author":"Coleman","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2021.108820_bib12","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.56427","article-title":"Chemical and structural investigation of the paroxetine-human serotonin transporter complex","volume":"9","author":"Coleman","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2021.108820_bib13","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1021\/acschemneuro.9b00617","article-title":"Investigation of the optical isomers of methcathinone, and two achiral analogs, at monoamine transporters and in intracranial self-stimulation studies in rats","volume":"11","author":"Davies","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108820_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lfs.2013.10.029","article-title":"Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology","volume":"97","author":"De Felice","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108820_bib15","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.bcp.2013.04.004","article-title":"Substituted methcathinones differ in transporter and receptor interactions","volume":"85","author":"Eshleman","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib16","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/s41386-018-0209-3","article-title":"The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter","volume":"43","author":"Gannon","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108820_bib17","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1021\/acschemneuro.6b00242","article-title":"Guidelines for homology modeling of dopamine, norepinephrine, and serotonin transporters","volume":"7","author":"Haddad","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108820_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0223-5234(00)00167-7","article-title":"Hydrophobicity: is LogP(o\/w) more than the sum of its parts?","volume":"35","author":"Kellogg","year":"2000","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108820_bib20","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1021\/cn4001236","article-title":"\"Deconstruction\" of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter","volume":"4","author":"Kolanos","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108820_bib21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0896-6273(94)90337-9","article-title":"Conducting states of a mammalian serotonin transporter","volume":"12","author":"Mager","year":"1994","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2021.108820_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jat\/bks136","article-title":"Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results","volume":"37","author":"Marinetti","year":"2013","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neuropharm.2014.02.016","article-title":"Pharmacology of novel synthetic stimulants structurally related to the \"bath salts\" constituent 3,4-methylenedioxypyrovalerone (MDPV)","volume":"87","author":"Marusich","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108820_bib24","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1110\/ps.072895107","article-title":"Fold assessment for comparative protein structure modeling","volume":"16","author":"Melo","year":"2007","journal-title":"Protein Sci."},{"key":"10.1016\/j.neuropharm.2021.108820_bib25","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/jm050797a","article-title":"1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors","volume":"49","author":"Meltzer","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108820_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nature12533","article-title":"X-ray structure of dopamine transporter elucidates antidepressant mechanism","volume":"503","author":"Penmatsa","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2021.108820_bib27","first-page":"83","article-title":"The antidepressant-sensitive dopamine transporter in Drosophila melanogaster: a primordial carrier for catecholamines","volume":"59","author":"Porzgen","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2003.08.054","article-title":"Monoamine transporters and psychostimulant drugs","volume":"479","author":"Rothman","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115513","article-title":"Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca(2+) channels as sensors","volume":"419","author":"Ruchala","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ceca.2014.04.003","article-title":"Electrical coupling between the human serotonin transporter and voltage-gated Ca(2+) channels","volume":"56","author":"Ruchala","year":"2014","journal-title":"Cell Calcium"},{"key":"10.1016\/j.neuropharm.2021.108820_bib31","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/bph.13043","article-title":"Steric parameters, molecular modeling and hydropathic interaction analysis of the pharmacology of para-substituted methcathinone analogues","volume":"172","author":"Sakloth","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib32","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","article-title":"Comparative protein modelling by satisfaction of spatial restraints","volume":"234","author":"Sali","year":"1993","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib33","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00213-015-4057-0","article-title":"Reinforcing and neurochemical effects of the \"bath salts\" constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats","volume":"233","author":"Schindler","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108820_bib34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jat\/bks047","article-title":"Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry","volume":"36","author":"Shanks","year":"2012","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jchemneu.2017.01.004","article-title":"Atypical dopamine efflux caused by 3,4-methylenedioxypyrovalerone (MDPV) via the human dopamine transporter","volume":"83\u201384","author":"Shekar","year":"2017","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2021.108820_bib36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","article-title":"Pharmacological characterization of designer cathinones in vitro","volume":"168","author":"Simmler","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108820_bib37","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/npp.2017.98","article-title":"N-alkylated analogs of 4-methylamphetamine (4-MA) differentially affect monoamine transporters and abuse liability","volume":"42","author":"Solis","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108820_bib38","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1523\/JNEUROSCI.17-03-00960.1997","article-title":"Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants","volume":"17","author":"Sonders","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108820_bib39","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00213-018-5103-5","article-title":"Using Ca(2+)-channel biosensors to profile amphetamines and cathinones at monoamine transporters: electro-engineering cells to detect potential new psychoactive substances","volume":"236","author":"Steele","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108820_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nature12648","article-title":"Structural basis for action by diverse antidepressants on biogenic amine transporters","volume":"503","author":"Wang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2021.108820_bib41","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nature14431","article-title":"Neurotransmitter and psychostimulant recognition by the dopamine transporter","volume":"521","author":"Wang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2021.108820_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature03978","article-title":"Crystal structure of a bacterial homologue of Na+\/Cl--dependent neurotransmitter transporters","volume":"437","author":"Yamashita","year":"2005","journal-title":"Nature"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821003750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821003750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:14:37Z","timestamp":1758438877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821003750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":42,"alternative-id":["S0028390821003750"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108820","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-conserved residues dictate dopamine transporter selectivity for the potent synthetic cathinone and psychostimulant MDPV","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108820"}}